Adenosine amine congener

Adenosine amine congener (CAS No.: 96760-69-9) is a synthetic adenosine analog that functions as a selective agonist of the A1 adenosine receptor, a G protein-coupled receptor implicated in neuromodulation, cytoprotection, and regulation of cellular metabolism. It exhibits high affinity and selectivity for A1 receptors over other adenosine receptor subtypes, with binding activity in the nanomolar range, leading to inhibition of adenylate cyclase activity and modulation of intracellular cAMP signaling pathways. This compound has been extensively utilized in preclinical research as a pharmacological tool to investigate A1 receptor-mediated neuroprotective mechanisms, particularly in models of ischemic brain injury and cochlear damage. In vivo studies demonstrate that Adenosine amine congener can attenuate noise- and cisplatin-induced cochlear injury, reduce auditory threshold shifts, and preserve inner and outer hair cell integrity, with efficacy influenced by dose and timing of administration, especially within early post-injury windows. Additionally, it has shown protective effects in cerebral ischemia models by enhancing neuronal survival in vulnerable hippocampal regions. Pharmacokinetic evaluations indicate a rapid plasma clearance with a short half-life following systemic administration, supporting its use in controlled experimental settings. Adenosine amine congener is therefore widely applied in neuroscience, otolaryngology, and receptor pharmacology research, where dosing regimens and exposure conditions are tailored to specific experimental paradigms.